] act on various cell types to modulate development, growth, and differentiation. All steroid hormones mediate these effects by binding to structurally related intracellular receptors, which in turn interact with defined sequences on regulatable genes to modulate their activity (1). Growth factors and cytokines act through membrane-bound receptors, the stimulation of which result in transcription of several genes involved in cell growth and differentiation (2, 3). The transition from proliferation to differentiation is a complex process requiring tightly coordinated control mechanisms.
In the past several years, a substantial amount of evidence has accumulated concerning the interaction of 1␣,25(OH) 2 D 3 with growth factors/cytokines in the regulation of coordinated cell growth and differentiation. The effects of 1␣,25(OH) 2 D 3 may be either antagonized or enhanced by growth factors/cytokines depending on the type of the cell, stage of differentiation, and duration of exposure to the steroid in vitro. The synthesis of growth factors/cytokines as well as their receptors can be altered by 1␣,25(OH) 2 D 3 in various cell types (4, 5). In this review, the impact of 1␣,25(OH) 2 D 3 on growth factor/cytokine synthesis and signaling is discussed particularly as it pertains to bone cells and keratinocytes.
The keratinocyte is an excellent model for the study of cellular differentiation in vitro (6, 7). It has recently become apparent that human keratinocytes are organized into stem cells, transit-amplifying cells, and terminally differentiated cells (8 -10). The hierarchical organization of keratinocytes is maintained in cell culture conditions (10). It has been shown that 1␣,25(OH) 2 D 3 is able to induce keratinocyte differentiation and suppress keratinocyte growth (11, 12). However, mitogenic effects of the sterol on keratinocytes have also been observed (13-17). This discrepancy seems to be related to concentrations of the hormone and its effects on the synthesis of various local factors implicated in the growth and differentiation of these cells.
It is well known that steroid hormones interact with autocrine/paracrine factors to exert their effects in bone (18 -21). 1␣,25(OH) 2 D 3 also affects synthesis and signaling of growth factors/and cytokines in bone. This interaction has an important impact on osteoblast and osteoclast development and function and, therefore, coordinates control of bone remodeling.
II. 1␣,25(OH) 2 D 3 as a Regulator of Cell Growth and Differentiation: Overview
Although the primary function of the active metabolite of vitamin D, 1␣,25(OH) 2 D 3 , is the regulation of calcium and phosphorus metabolism, it also plays important roles in the regulation of growth and differentiation in various cells and tissues, including bone cells and keratinocytes (4), cartilage (22), and hematopoietic cells (23). The observation that 1␣,25(OH) 2 D 3 suppresses cellular growth and induces differentiation of myeloblasts and promyelocytes into macrophages (24), and that it inhibits the proliferation of malignant melanoma cells (25), initially showed that the sterol functioned in areas distinct from its classical transcellular calcium transport function. In a general sense, 1␣,25(OH) 2 D 3 inhibits the proliferation of the cells and induces them toward a more differentiated state in most cell types, such as osteoblasts (26). In dendritic cells, however, 1␣,25(OH) 2 D 3 promotes a persistent state of immaturity leading to inhibition of cellular immune responses (27, 28) . Therefore, cell culture conditions, cell types, species differences, as well as interactions with growth factor/cytokine signaling are important determinants of the diversity of the biological actions mediated by the sterol.
The effects of 1␣,25(OH) 2 D 3 are primarily mediated by the vitamin D receptor (VDR), which is a member of the nuclear receptor superfamily (29 -32). Nuclear receptors activate transcription by binding to response elements that consist of hexameric core binding motifs in promoters of their target genes (33). The VDR is a 48-kDa zinc finger protein (34, 35), which activates transcription by binding to vitamin D response elements (VDREs) within the promoter of vitamin D-responsive genes, either as a homodimer (33, 36) or a heterodimer with the retinoid acid X receptor-␣ (37-40), retinoic acid receptor (41, 42), or thyroid hormone receptors (43).
1␣,25(OH) 2 D 3 regulates the expression of growth factor/ cytokine synthesis as well as receptor expression and modulates growth and differentiation in many cell types including epithelial, mesenchymal, neural, vascular endothelial, immune cells, and chondrocytes (Refs. 44 -68 and Table 1 ). As seen in Table 1 , the increased growth factor and cytokine synthesis by 1␣,25(OH) 2 D 3 generally leads to the inhibition of cellular growth and, in some instances, induction of differentiation. The sterol also exerts immunosuppressive effects through local factors (Table 1) . In this review, we will confine our remarks to its effects on growth factors/cytokines using keratinocytes and bone cells as a paradigm. We will also provide information concerning the molecular mechanisms of the interaction of 1␣,25(OH) 2 D 3 with growth factor/cytokine synthesis and signaling when data are available.
III. Effect of 1␣,25(OH) 2 D 3 on Growth Factors and Cytokines: Role in Keratinocyte Growth and Differentiation and Epidermal Pathologies

A. Physiology and pathophysiology of keratinocyte growth and differentiation
The growth and differentiation patterns of epidermal keratinocytes in skin are schematically illustrated in Fig. 1 . It has become apparent recently that human keratinocytes are organized into stem cells, transit-amplifying cells, and terminally differentiated cells (8 -10). Stem cells have a high proliferative capacity and express ␤1,4 integrins. In the presence of adequate levels of calcium, keratinocytes progress from a proliferative status to a differentiated state characterized by irreversible growth arrest, induction of differentiationspecific gene products, and the ability to synthesize cornified envelopes. The cornified envelope is formed by the crosslinking of precursor molecules such as involucrin and lorucrin into an insoluble, durable membrane-associated scaffold by the membrane-bound enzyme transglutaminase. During the progress of differentiation, a successive increase occurs in involucrin, transglutaminase, and cornified envelope formation (69, 70). With the appearance of the cornified envelopes, previously up-regulated transglutaminase and 25-hydroxyvitamin D 3 -1␣-hydroxylase activities fall concomitantly, and a reciprocal increase in 25-hydroxyvitamin D 3 -24-hydroxylase activity occurs (69). Stem cells play a central role in maintaining keratinocyte turnover and epidermal integrity and mass balance. In normal epidermis, the majority of stem cells are quiescent (arrested in G o ), but in hyperproliferative skin disorders such as psoriasis, they enter the cell cycle at an enhanced rate (71, 72 ). An increased rate of stem cell proliferation is believed to be responsible, in part, for epidermal hyperplasia. The proliferative state of stem cells is maintained by various growth factors, primarily those of the epidermal growth factor (EGF) family [such as amphiregulin (AR), TGF␣, and heparin-binding EGF], as well as TGF␤, IGF-I, and keratinocyte growth factor (KGF or FGF7) and cytokines [IL-1, IL-6, IL-8, ␤-interferon (IFN)] (72-74). We have previously shown that 1␣,25(OH) 2 D 3 has a biphasic effect on keratinocyte growth that is concentration dependent (14). In defined medium, free of serum, sterol, and pituitary extract, 1␣,25(OH) 2 D 3 suppresses keratinocyte growth at concentrations greater than 10 Ϫ8 m, whereas a stimulation occurs at concentrations less than 10 Ϫ9 m (14). In serum-containing medium, the sterol inhibits keratinocyte growth at all concentrations.
B. Modulation of keratinocyte growth and differentiation by 1␣,25(OH)
The administration of 1␣,25(OH) 2 D 3 to keratinocytes is associated with an induction of 25-hydroxyvitamin D 3 -24-hydroxylase activity, inhibition of 25-hydroxyvitamin D 3 -1-␣ hydroxylase activity (76), an induction in skin calcium-binding protein synthesis (77), and inhibition of PTHrP production (78, 79). Cultured human keratinocytes do not possess receptors for PTHrP (80) and, therefore, they are not considered as a target for this peptide. However, PTHrP is implicated in the regulation of keratinocyte growth and differentiation in vivo. In a recent study, the absence of PTHrP appeared to result in the reduction of the basal keratinocyte compartment and premature acquisition of suprabasal and granular differentiation markers, whereas overexpression of the peptide generated reciprocal findings (81). These findings suggest that the inhibition of PTHrP by 1␣,25(OH) 2 D 3 contributes to some extent to the growth-inhibitory and prodifferentiative effects of the sterol on keratinocytes.
The growth-inhibitory and prodifferentiative effect of 1␣,25(OH) 2 D 3 is associated with a decrease in c-myc mRNA levels (12). 1␣,25(OH) 2 D 3 increases involucrin and transglutaminase activity in keratinocytes, and it increases cornified envelope formation (11, (82) (83) (84) (85) (86) ). An increase in protein kinase C (PKC) activity and translocation of PKC to cellular membranes has been described (87, 88).
The level of expression of the VDR is a major determinant of cellular 1␣,25(OH) 2 D 3 responsiveness in keratinocytes. It has been suggested that VDR expression in normal human keratinocytes is linked to cell cycle control (89). VDR levels are markedly decreased by arresting the cells in G 0 , at the G 1 -S border, or during the mitotic metaphase. In each of these cases, VDR is rapidly induced when the cells are stimulated to reenter cell cycle. This indicates that VDR expression is restricted to cycling cells but not to a particular cell cycle phase. Proliferating cells should therefore be considered as preferential vitamin D target cells. This is in accord with the identification of the basal keratinocyte as the main VDRcontaining cell in the epidermis.
Although previous findings have indicated an antiproliferative effect of 1␣,25(OH) 2 D 3 on keratinocytes ex vivo (90) and in vitro (12, 91), there are also studies reporting a mitogenic effect mediated by the sterol (13-17). Similar discrepancies also exist in the clinical effects of the sterol. (12, 112, 113) . The receptor numbers have been determined by radioreceptor assays in these studies (12, 112, 113). The inability of the radiolabeled EGF binding assays to detect the receptors occupied by the autocrine and juxtacrine ligands defined by Garach-Jehoshua et al. (13) might be another explanation for the variability in HER/ ErbB levels described previously (12, 85, 86). It is likely that the proliferative action of the sterol in skin seems to be related to its action through EGF-related/HER signaling pathways.
TGF␤.
TGF␤ is a 25-kDa peptide that has pleiotropic effects within the skin and epidermis. Although it can stimulate the growth and metabolic activity of fibroblasts (114, 115), it is a major growth-inhibitory autocrine factor expressed by keratinocytes (116 -118). TGF␤, which is expressed by human keratinocytes, arrests keratinocyte growth in a reversible and G 1 phase-specific manner (119). Overexpression of a constitutively active form of TGF␤ targeted to epidermis markedly inhibits keratinocyte proliferation without affecting the terminal differentiation markers discussed above (120) . In vivo studies demonstrate hyperproliferative epidermis in animals with targeted disruption of the TGF␤ gene (121). In psoriatic plaques, TGF␤ is detectable but restricted to suprabasal cells (122, 123 3 was associated with a time-and dose-dependent increase in the TGF␤2 concentrations in the supernatant medium of cultured human keratinocytes (91). However, in contrast to the previous observations (124, 125), we did not observe a change in TGF␤1 concentrations. We also observed that antibodies directed against TGF␤ partially blocked the suppression of cellular growth mediated by the sterol (91). Taken together, these results clearly indicate that 1␣,25(OH) 2 D 3 inhibits keratinocyte growth by a mechanism that involves, at least in part, an increase in the release of TGF␤. This mechanism may provide a rationale for the beneficial effects of the sterol in hyperproliferative as well as preneoplastic epidermal skin disorders. (Table 3) .
Platelet-derived growth factor (PDGF
a. TGF␤. It is well known that TGF␤ is synthesized by both osteoblasts and osteoclasts and abundantly stored in extracellular bone matrix, suggesting autocrine and paracrine mechanisms of action (155, 156). TGF␤ plays an important role in coupling bone formation to previous bone resorption (157). TGF␤ is an essential regulator of osteoblast replication and function (158). In normal osteoblasts, TGF␤ stimulates cell growth and induces changes in cell morphology, cytoskeletal protein organization, and synthesis (159, 160). TGF␤ directly increases the steady-state rate of osteoblastic differentiation from osteoprogenitor cell to terminally differentiated osteocyte and thereby increases the final density of osteocytes embedded in the bone matrix in vivo (161).
The biological effects of TGF␤ are mediated through cellspecific transmembrane serine/threonine kinase receptors in osteoblasts (162) . The heterodimeric interaction of liganded type I and type II receptors is needed for signal transduction and, consequently, mediation of the different biological responses (162) . TGF␤ signal transduction and transcriptional control are mediated in the cells by a family of receptor substrates, the Smad proteins (mothers against decapentaplegic-related proteins) that translocate to the nucleus and act as transcription factors (163) . Smad3 plays an essential role in TGF␤-mediated signal transduction. It has been shown that targeted disruption of Smad3 in mice markedly blunts the cellular effects of TGF␤ (164) .
If primary human osteoblastic cell cultures are treated with 1␣,25(OH) 2 D 3 and TGF␤, they stimulate spindleshaped cells to become stellate in appearance and increase the number of cytoplasmic processes (165) . TGF␤ increases 3 H-thymidine incorporation and 1␣,25(OH) 2 D 3 reduces this effect. In contrast, procollagen type I synthesis and secretion are increased in a dose-dependent manner in the presence of TGF␤, and these effects are not suppressible by 1␣,25(OH) 2 D 3 . TGF␤ and 1␣,25(OH) 2 D 3 each marginally increase alkaline phosphatase activity whereas cotreatment synergistically increases alkaline phosphatase activity in a dose-and time-dependent manner (165) . TGF␤ suppresses 1␣,25(OH) 2 D 3 -induced osteocalcin expression and secretion (165, 166) . In summary, these data suggest that TGF␤ stimulates the human osteoblast to actively produce collagen matrix and proliferate. 1␣,25(OH) 2 D 3 stimulation may induce cells to advance to an endstage where cell proliferation is reduced and osteocalcin expression is promoted.
Evidence is now available with regard to the mechanisms of 1␣,25(OH) 2 D 3 Fig. 5 ). Taken together, these data suggest that antiproliferative effects of 1␣,25(OH) 2 D 3 on osteoblasts is mediated, at least in part, by TGF␤. The release of TGF␤, which also influences the activity of the adjacent osteoclasts, plays an important role in bone remodeling. The molecular mechanisms by which 1␣,25(OH) 2 D 3 enhances the TGF␤ expression have been recently highlighted by several studies. Because VDREs, to which the VDR binds, are comprised of direct repeats, palindromes, or inverted palindromes of the hexameric core binding motif RRKNSA (R ϭ A or G, K ϭ G or T, S ϭ C or G) (33, 43, 169), we investigated whether 1␣,25(OH) 2 D 3 induces TGF␤2 expression via such repeat elements. We transiently transfected human fetal osteoblasts (hFOB cells) with a series of TGF␤2 promoter/human GH reporter constructs (170) . We identified two imperfect direct repeat sequences (TGTAGAA-CAAGTAGA and AATGAAGTTGGTGGA) in the TGF␤2 promoter where the heterodimers of the VDR and RXR␣ bind and, therefore, mediate the effects of 1␣,25(OH) 2 D 3 (Ref. 170 and In recent years, evidence has accumulated with respect to the interactions between 1␣,25(OH) 2 D 3 and events downstream of TGF␤ receptor stimulation. Yanagisawa et al. (172) showed that Smad3, a regulatory Smad, acts as a coactivator of VDR and positively regulates the vitamin D signaling pathway. These data suggest that TGF␤ and 1␣,25(OH) 2 D 3 signaling pathways by which osteoblast gene expression is induced converge on Smad3. The consequences of the targeted disruption of Smad3 in osteoblasts were recently evaluated by Borton et al. (173) . They showed that TGF␤ can no longer inhibit the differentiation of osteoblasts in Smad3 null mice; nevertheless, stimulation of the proliferation remains intact (173) . The clinical consequence of the lack of Smad3 in these mice was osteopenia, which is attributed to a decreased rate of bone formation. The reduction in bone formation is associated with increased osteocyte number and apoptosis (173) . These results suggest that inhibition of osteoblast differentiation and stimulation of osteoblast proliferation is regulated through divergent mechanisms by TGF␤. Whether 1␣,25(OH) 2 D 3 signaling is implicated in the diversity of these TGF␤ actions on osteoblasts is currently not known. In view of the complex interplay between TGF␤ and 1␣,25(OH) 2 D 3 , it is highly likely that other factors downstream from the signaling pathway are also operative. As an example, Yanagi et al. (174) have recently demonstrated that Smad7, an inhibitory Smad, abrogates the Smad3-mediated potentiation of VDR function. However, more work is required to clarify molecular mechanisms of the interplay between TGF␤ and 1␣,25(OH) 2 D 3 in the context of inhibitory Smads and other Smad coactivator and corepressor partners with which Smads cooperate.
b. IGFs and IGF binding proteins (IGFBPs)
. IGF-I and II are traditionally known as the mediators of GH action (175) . In addition to their major roles in the growth and differentiation of cartilage, they directly affect bone. IGF-I and IGF-II were found to stimulate cell multiplication as well as collagen synthesis in fetal rat calvaria (176, 177) and in primary osteoblast-enriched cell cultures (178, 179) . Studies have shown that IGF-I is also a mediator for some of the anabolic effects of PTH in calvaria cultures (180) . IGF-I and -II synthesis and secretion have been detected in the conditioned media of organ cultures (181) , osteoblast-like cell cultures (178) , and preosteoblastic human bone marrow stromal cells (182) . IGF receptor expression has been demonstrated in clonal osteoblastic MC3T3-E1 cells (183) . Therefore, it is clear from these observations that IGFs locally mediate for osteoblast development and function. The synthesis and release of IGFs during bone resorption suggest a role of these growth factors in the coupling of bone resorption with formation.
It has previously been reported that there is a synergistic interaction between IGF-I and 1␣,25(OH) 2 D 3 with respect to the stimulation of alkaline phosphatase activity in osteoblastic cell lines (184 Ϫ10 to 10 Ϫ7 m) exerts no effect on either IGF-I or IGF-II mRNA expression in preosteoblastic human bone marrow cells. However, Chenu et al. (185) showed that 1␣,25(OH) 2 D 3 , in a time-and dose-dependent manner, increased IGF-I release from human osteoblast-like cells in short-term cultures. Linkhart and Keffer (186) have found that 1␣,25(OH) 2 D 3 stimulates IGF-I but inhibits IGF-II release by cultured neonatal mouse calvarial cells, suggesting differential regulation of IGF subtypes by the sterol. The results of these studies suggest that the effect of 1␣,25(OH) 2 D 3 on IGF synthesis and release are divergent, possibly depending on the differences in cell types, culture conditions, and differentiation status of the cells.
1␣,25(OH) 2 D 3 may also exert modulatory effects on IGF receptor expression by osteoblasts. For example, Kurose et al. (183) found that the affinity and hormone binding capacity of VDRs were not affected by IGF-I in the MC3T3-E1 osteoblastic cell line. However, 1␣,25(OH) 2 D 3 significantly induced IGF-I receptor expression. This was evident by Scatchard analysis, which revealed a significant increase in IGF-I binding sites by 50% after treatment for 3 d with 5 ϫ 10 Ϫ11 m 1␣,25(OH) 2 D 3, without any change in affinity (183) .
The bioactivity of IGFs is regulated through their interaction with a group of high-affinity IGFBPs. At least six IGFBPs (IGFBPs 1-6) have been identified and were found to have a variety of biological effects that are both IGFBP and cell type specific (187) . The activities of IGFBPs are regulated through changes in their rates of degradation by multiple specific and nonspecific proteases and protease inhibitors (188, 189) . The exact functions of the different IGFBPs in bone metabolism are complex and are not yet fully understood. However, increasing evidence suggests that they may modulate the activities of IGFs. For example, exogenous IGFBP-5 enhances the mitogenic potential of IGF-I (190) or IGF-II (191) added to mouse osteoblast-like cells in vitro and has an important role in the storage of IGF-II in bone matrix (191) . IGFBP-1 (192) , , and IGFBP-4 (194) have been shown to suppress the functions of IGF actions in human osteoblast-like cells. IGFBP-2 has been shown to potentiate (195) or antagonize (196, 197 ) the IGF-mediated effects, and its role in osteoblast biology is not precisely known.
In human preosteoblastic bone marrow stromal cells, 1␣,25(OH) 2 D 3 has been found to increase steady-state mRNA levels of IGFBPs 2, 3, and 4 (182). Western ligand blot analyses revealed consistently the stimulation of secretion of the IGFBPs (182) . 1␣,25(OH) 2 D 3 stimulates IGFBP-5 mRNA expression in cultured neonatal calvarial cells (198) and the osteoblastic UMR-106 cell line (199) . Increased mRNA expression and secretion of IGFBP-3 and 4 have also been observed in human osteoblastic cells in several other studies (200 -203) . As a common point, the increase in the expression of these IGFBPs was not associated with increased proteolytic activity. The increase in mRNA and protein levels of IGFBPs requires continuous exposure to 1␣,25(OH) 2 D 3 for more than 48 h (182) , suggesting that these changes are secondary to effects on immediate responsive genes. As no consensus VDRE has been found in the promoter regions of the IGFBPs, it is plausible that 1␣,25(OH) 2 D 3 effects are mediated through other signaling pathways such as cAMP or AP-1 transcription factors, which have been shown to mediate some of the genomic effects on components of the IGF system (204, 205) .
Given the inhibitory effects of IGFBPs in IGF actions on bone cells (206, 207) , it is plausible that the inhibitory effects of 1␣,25(OH) 2 D 3 on bone formation may be mediated, at least in part, by the enhanced production of inhibitory IGFBPs. However, the regulatory roles of IGFBPs in the effects of 1␣,25(OH) 2 D 3 on bone cell biology are complex and deserve further evaluation. Based on earlier observations that addition of excessive amounts of IGFBPs to cell cultures resulted in variable effects, more physiological approaches are required. This will rely on the assessment of endogenous levels of IGFBPs and development of IGFBP-specific neutralizing antibodies that will prevent interaction with IGFs.
c. Nerve growth factor (NGF)
. NGF belongs to a family of neurotrophic factors named neurotrophins, which includes brain-derived neurotrophic factor and neurotrophins 3, 4, and 5 (208). NGF was initially described on the basis of its trophic effects on sympathetic and some sensory neurons in the peripheral nervous system (208) . However, its role now extends to cells belonging to the endocrine and immune systems. In the mouse fibroblastic cell line L929, the expression of the NGF gene has been shown to be positively regulated by an activator of PKC, the phorbol 12-myristate 13-acetate (209) , and 1␣,25(OH) 2 D 3 (51). The presence of NGF in the embryonic bone of the chick has been shown by immunochemistry (210) , as has the expression of NGF family neurotrophins in the MC3T3-E1 mouse osteoblastic cell line (211) . The regulation of NGF expression by 1␣,25(OH) 2 D 3 in osteoblasts was first studied by Jehan et al. (212) . In the ROS 17/2.8 rat osteoblastic cell line, they showed that 1␣,25(OH) 2 D 3 caused a dose-dependent increase in NGF mRNA expression. Binding of radiolabeled NGF displayed the presence of low-affinity receptors for the growth factor in these cells (212) . In the rat ROS17/2.8 osteoblastic cell line, we have shown that treatment with 1␣,25(OH) 2 D 3 for 6 h resulted in a dose-dependent increase in NGF expression (213) .
The biological significance of the 1␣,25(OH) 2 D 3 -induced NGF expression by osteoblastic cells has not yet been clarified. Regeneration after limb amputation can be successfully induced by transplanting nervous tissue to the lesioned limb (214, 215) , and symphatectomy may result in the loss of a trophic influence important in the regulation of osteogenesis (216) . More recently, it was shown that topical application of NGF improves fracture healing in rats (217) . However, whether NGF produced by bone cells is associated with the nerve supply of bone, is directly implicated in bone formation, or acts on bone marrow cells to promote proliferation remains to be further explored.
The molecular mechanisms by which 1␣,25(OH) 2 D 3 induces NGF expression in osteoblasts have not yet been fully understood. The NGF gene contains an AP-1 site within the first intron, 35 bp downstream from the transcription initiation site (218) . This AP-1 site has been shown to be functionally required for basal level NGF transcription in fibroblasts (219) . Members of the fos and jun family of transcription factors are known to bind to these AP-1 sequences. Indeed, lesion-induced increases in NGF expression have been mediated by c-fos (220) . In a previous study from our laboratory (213), we have shown that 1␣,25(OH) 2 D 3 induces NGF expression in ROS 17/2.8 osteoblastic cells indirectly by increasing AP-1 binding activity (213) .
d. Vascular endothelial growth factor (VEGF).
Osteoblasts are located in proximity to endothelial cells. It is highly likely that a mutual communication exists between endothelial cells and parenchymal cells, as demonstrated in liver and thyroid (221, 222) . Osteoblasts and preosteoblastic progenitor cells have been found to locate adjacent to endothelial cells in blood vessels at sites of new bone formation (223) . Vascular invasion is a prerequisite for endochondral bone formation and fracture healing (224) . Factors produced by endothelial cells may therefore affect osteoblast function or differentiation and vice versa (225, 226) . As a clinical clue to the interaction between osteoblasts and endothelial cells, older subjects and patients with osteoporosis have been shown to have decreased blood vessels in their skeletal tissue that is accompanied by a parallel decrease in osteoblast number (227, 228) . In this cross-talk between endothelial cells and osteoblasts, VEGF, which acts as an angiogenic factor, may play an important role (59). A recent study by Gerber et al. (229) revealed that blocking the action of endogenous VEGF inhibits both bone formation and resorption in juvenile mice.
VEGF, a homodimeric protein with a signal peptide, specifically stimulates endothelial cell proliferation by binding to VEGF receptors (Flt-1 and KDR) that are expressed exclusively on the cells (230, 231) . During osteoblast development, both VEGF and VEGF receptor expression increases in parallel with the advancement of the cell differentiation (232) . VEGF mRNA expression has been found to be induced (Fig. 7) (59) . In view of these observations, it is plausible to state that there is a mutual communication between osteoblasts and endothelial cells in bone. The anabolic effects of 1␣,25(OH) 2 D 3 on osteoblasts are mediated in a paracrine manner and enhanced by a VEGF/VEGF receptor system between osteoblasts and endothelial cells.
The exact mechanism by which 1␣,25(OH) 2 D 3 increases VEGF expression in osteoblasts is not currently known. VEGF promoter is a target for 1␣,25(OH) 2 D 3 despite the lack of classical response elements in it (233) . In a manner similar to prostaglandin E 2 -induced VEGF mRNA expression in rat osteoblastic cells (236) , the 1␣,25(OH) 2 D 3 -stimulated expression of VEGF mRNA in human osteoblast-like cells was completely inhibited by H-7, a general inhibitor of protein kinases, but only partially inhibited by staurosporine, a more specific inhibitor of PKC (234) . Therefore, although there are several reports showing that the 1␣,25(OH) 2 D 3 activates PKC at physiological concentrations (237, 238) , this activation does not seem to be completely responsible for the induction of VEGF expression in osteoblasts.
e. EGF family. EGF and related family members have been shown to be important growth factors for a variety of cells including numerous epithelial and epidermal cells (discussed further in Section III.C.1) in vivo and in vitro. Bone cells express EGFRs (239, 240) , and EGF has been demonstrated to stimulate DNA synthesis as well as to enhance growth of osteoblast-like cells (241) . EGF has also been shown to increase bone resorption (242, 243) , decrease collagen synthesis (244) , and inhibit the formation of mineralized nodules (245) . Previously, PTH has been shown to increase the expression of EGFR in the UMR 106-01 osteoblastic cell line (246) . In an early study by Petkovich et al. (247) , 1␣,25(OH) 2 D 3 caused a dose-and time-dependent increase in EGFR expression in RCJ 1.20 rat calvarial cells. The increase in EGFRs potentiated the effect of EGF on anchorage-dependent and anchorageindependent growth of these cells (247) . More recently, the stimulatory effect of 1␣,25(OH) 2 D 3 on EGFR expression was also confirmed in UMR 106-01 osteoblast-like cells (248) . In this study, the effects of 1␣,25(OH) 2 D 3 on EGFRs were completely abolished in the presence of retinoic acid (248) . Because EGF and other family members are important factors in the growth and development of osteoblasts, modulation of its receptors by 1␣,25(OH) 2 D 3 plays an important role in its effects on these cells.
B. Osteoclasts
1. Formation and function of the osteoclast. As discussed previously, bone resorption is one arm of the bone remodeling process that is usually balanced by bone formation to maintain bone mass. Under normal conditions, bone-resorbing osteoclasts are present in appropriate numbers, and they cycle between active and inactive states in a tightly regulated fashion. When in balance, the remodeling process involves equal and linked participation of both osteoblasts and osteoclasts. Deviation of the balance in favor of resorption leads to bone loss and, therefore, osteoporosis (249) . Osteoclasts resorb bone by a complex, multistep process that occurs in an orderly sequence and utilizes cross-reacting intracellular signaling pathways (249, 250) . The earliest identifiable osteoclast precursors are derived from colony forming unit-granulocyte/macrophage (CFU-GM) from the granulocyte/macrophage lineage (249) . Osteoclast precursor cells are attracted to regions of mineralized bone matrices that are identified in an unknown way to undergo resorption to maintain plasma calcium levels.
The osteoclast life span can be subdivided into distinct stages as follows: 1) homing of the precursor cells (CFU-GM) to bone surfaces and proliferation (formation of preosteoclasts), 2) fusion of mononuclear preosteoclasts into multinucleate immature osteoclasts, 3) development of polarity through adherence to bone and assembly of an acidifying resorptive apparatus (ruffled border) indicative of cellular activation, 4) detachment and final inactivation that ends in apoptosis. As discussed in detail below, endocrine and local control by several factors are effective in osteoclastogenesis and function of the cells.
Endocrine and local control of osteoclast activity.
Osteoclast function is regulated by a variety of hormones, including 1␣,25(OH) 2 D 3 . Bone resorption is stimulated by PTH and 1␣,25(OH) 2 D 3 , whereas it is inhibited by sex steroids (discussed earlier) and calcitonin. Most stimulators appear to act indirectly, in contrast to most inhibitors, which act directly. PTH action in bone is a good example for the indirect mechanism. PTH increases bone resorption by increasing the activity and number of osteoclasts (249) . However, it has also been noted that isolated osteoclasts do not express PTH receptors and therefore, isolated osteoclasts can not directly respond to PTH (251, 252) . The addition of osteoblasts to isolated osteoclasts restores the ability of the osteoclasts to resorb bone in response to PTH (251) . This finding suggests that PTH activates osteoclasts indirectly by stimulating osteoblasts and perhaps osteoblast precursors, which then activate osteoclasts.
There are several growth factors and cytokines that are involved in the local control of osteoclastogenesis and osteoclast function (Table 4) .
As seen in Table 4 , the effects of these factors on osteoclast formation is in accordance with their effects on osteoclast function, except in the case of macrophage-colony stimulating factor (M-CSF). M-CSF stimulates osteoclastogenesis de- Table 3 and Fig. 8 , and discussed in the following sections.
a. RANKL/RANK/osteoprotegerin (OPG) system. This novel cytokine system, a member of the TNF ligand and receptor superfamily, plays an important role in osteoclast biology (268, 272) . In a manner similar to the TNF␣ and IL-1 cytokine systems, this newly recognized cytokine system also consists of 1) a ligand, RANKL, that exists in a cell-bound and soluble form; 2) a cell-bound receptor, RANK; and 3) a secreted decoy receptor, OPG (268, 273) . OPG is expressed ubiquitously and abundantly by a variety of cell types including the osteoclast precursors (274) . Various skeletal and extraskeletal cells such as stromal cells, osteoblasts, osteoclasts, mesenchymal periostal cells, chondrocytes, and endothelial cells express RANKL (275) (276) (277) (278) (279) . It has recently been demonstrated that activated T lymphocytes express RANKL to support osteoclast formation (280) . RANKL may promote osteoclast differentiation (281) (282) (283) , activation (284), survival (285) , and adherence to bone surface (286) through RANK. As expected, activation of its decoy receptor, OPG, causes opposite effects.
Regulation of RANKL and OPG gene expression and OPG secretion has been a subject of several studies. RANKL/ RANK/OPG system plays an important role in the coupling of osteoblasts with osteoclasts and is under the influence of local factors and hormones (Fig. 8) . Analysis of the RANKL gene promoter showed response elements for vitamin D and glucocorticoids (287, 288) , suggesting regulation of RANKL by these hormones. Estrogen has the ability to enhance OPG mRNA steady-state levels and OPG protein secretion in human osteoblasts, which contributes to its inhibitory effects on bone resorption (289) . 1␣,25(OH) 2 D 3 is also involved in the regulation of RANKL and OPG both directly and indirectly, through local factors (Fig. 8) . Nakashima et al. (290) showed that treatment of murine osteoblasts and stromal cells with 1␣,25(OH) 2 D 3 resulted in increases in membrane-bound RANKL expression and inhibition of OPG production. In another study, Horwood et al. (291) observed that PTH, IL-11, and 1␣,25(OH) 2 D 3 increased the RANKL/OPG ratio in mouse calvaria. The inhibition of OPG by 1␣,25(OH) 2 D 3 was also observed in the human fetal osteoblastic cell line, but not in human preosteoblastic marrow stromal cells (292) . Recently, Thomas et al. (293) provided data about the effect of the differentiation state of the osteoblastic cells in the regulation of RANKL/OPG ratio by 1␣,25(OH) 2 D 3 . OPG mRNA expression was increased in primary murine osteoblastic cultures after the onset of mineralization relative to less mature cultures, but showed no alteration with 1␣,25(OH) 2 D 3 treatment (293). In contrast, basal RANKL mRNA expression did not change during differentiation but was significantly enhanced by 1␣,25(OH) 2 D 3 treatment at all times. The stimulatory effects of 1␣,25(OH) 2 D 3 on RANKL were lessened in more mature cultures (293) . Taken together, these results suggest that 1␣,25(OH) 2 D 3 increases the RANKL/OPG ratio and promotes osteoclastogenesis (Fig. 8) .
b. IL-1. IL-1 was one of the earliest cytokines to be identified as having a regulatory role in bone cell function and remains one of the most potent bone-resorbing agents (294) . In a previous study by Merry and Gowen (295) , human osteoblast-like cells were used to determine the modulators of IL-1 expression. They found that hydrocortisone (10 Ϫ8 m) treatment resulted in the suppression of TGF␤ and IL-1␤ mRNA expression. 1␣,25(OH) 2 D 3, however, had no effect on IL-1␤, but it increased TGF␤ expression (295) . Furthermore, 1␣,25(OH) 2 D 3 failed to reverse the hydrocortisone-induced suppression in IL-1␤ expression. These results suggest that TGF␤ and IL-1␤ are differentially regulated in osteoblasts and that 1␣,25(OH) 2 D 3 seems to have no direct effect on IL-1␤ expression. Interestingly, Lacey et al. (296) demonstrated that 1␣,25(OH) 2 D 3 stimulates the expression of type 1 IL-1 receptors, which mediate the IL-1-induced IL-6 production. As discussed below, IL-6 is also a bone-resorbing cytokine that contributes to the effects of 1␣,25(OH) 2 D 3 .
c. IL-4. Apart from being an immunomodulatory cytokine, IL-4 has been shown to inhibit bone resorption induced by a variety of osteolytic factors in vitro (297) and in vivo (298) . IL-4 significantly antagonizes osteoclast generation in vitro (299) . It has been shown that IL-4 receptor is expressed by osteoblasts (300), and stimulation of the cells with 1␣,25(OH) 2 D 3 caused steady-state increases in IL-4 mRNA levels in a time-dependent manner. Therefore, it is highly likely that inhibitory effects of IL-4 on osteoclast are mediated by osteoblasts, and 1␣,25(OH) 2 D 3 is implicated in this process. Therefore, local control mechanisms involved in IL-4-mediated regulation of bone resorption by osteoblasts should be further investigated.
d. IL-6. Most of the evidence suggests that IL-6 affects neither the bone-resorbing capacity of mature osteoclasts (301, 302) , nor their differentiation in mouse parietal bones (303) , but IL-6 does stimulate the proliferation of osteoclast progenitor cells (304) . There is much evidence to indicate that IL-6 is produced by osteoblast-like cells and acts on osteoclasts to exert its effects (305) . In a previous study (306) , 1␣,25(OH) 2 D 3 did not stimulate IL-6 production in mouse parietal osteoclasts but induced their proliferation. Similarly, 1␣,25(OH) 2 D 3 caused only marginal elevations in mouse stromal/osteoblast-like cell lines (307) . On the other hand, there is convincing evidence that stimulatory effects of 1␣,25(OH) 2 D 3 on osteoclastogenesis could be mediated in part by IL-6. In a recent study, Schiller et al. (308) found that 1␣,25(OH) 2 D 3 -induced IL-6 expression failed to stimulate osteoclastogenesis in mouse bone marrow cultures. However, they also reported that neutralizing antibodies against IL-6 and anti-IL-6 receptor partly blocked the 1␣,25(OH) 2 D 3 -stimulated osteoclastogenesis (308) . Apart from a ligandbinding domain, IL-6 receptor also has a non-ligand-binding but signal-transducing component, gp130 (309) . In a recent study, Gao et al. (310) have reported that 1␣,25(OH) 2 D 3 significantly increased gp130 expression in preosteoclastic mouse bone marrow stromal cells without affecting IL-6 receptor. Moreover, both ligand-binding domain and gp-130 were stimulated by 1␣,25(OH) 2 D 3 in marrow mononuclear cells (310) . The treatment of tartrate-resistant acid phosphatase-positive mononuclear cells with IL-6 clearly increased their bone-resorbing capacity (310) . These results suggest 1␣,25(OH) 2 D 3 indirectly increases the bone-resorbing capacity of osteoclasts via stimulating IL-6 receptor and gp130 expression.
e. IL-8. IL-8 is a chemokine that is involved in many inflammatory disease states associated with local bone loss such as rheumatoid arthritis (311) . Human osteoclasts synthesize and secrete high constitutive and inflammationstimulated levels of IL-8, which enhance bone resorption and recruitment of inflammatory cells (312) . IL-8 release from the cells is induced by proinflammatory cytokines IL-1␣ and TNF␣, but suppressed by IFN␥, dexamethasone, and 1␣,25(OH) 2 D 3 (312) . Thus, these results suggest that 1␣,25(OH) 2 D 3 might be beneficial in the prevention of local bone loss in inflammatory disease states, such as rheu-matoid arthritis, by inhibiting IL-8 expression in osteoclasts.
f. IL-11. IL-11 is a functionally pleiotropic cytokine that was isolated from a bone marrow-derived stromal cell line (313) . Similar to IL-6, IL-11 receptor also contains gp130 as a signal transducer (309) . Several lines of evidence suggest that IL-11 is an important osteotropic factor. IL-11 itself is produced by human osteosarcoma SaOS-2 cells (314) , and Girasole et al. (259) have shown that IL-11, in a dose-dependent manner, stimulated osteoclast-like multinucleated cell formation in cocultures of mouse osteoblasts and bone marrow cells. The effect of IL-11 on osteoclast function, however, is not yet clear.
Romas et al. (315) examined IL-11 production by primary mouse osteoblasts and the effects of rat monoclonal antimouse glycoprotein 130 (anti-gp130) antibody on osteoclast formation in a coculture system that consists of osteoblasts and marrow cells. They observed that osteotropic factors [1␣,25(OH) 2 D 3 , PTH and IL-1] had no effect on IL-11 steadystate mRNA levels. However, steady-state gp130 mRNA levels were significantly induced by these factors. In cocultures, the formation of multinucleated osteoclast-like cells in response to IL-11 was suppressed, in a dose-dependent manner, by anti-gp130 monoclonal antibodies. Furthermore, adding anti-gp130 antibody abolished osteoclast formation by the osteotropic factors including 1␣,25(OH) 2 D 3 (315) . These results suggest that 1␣,25(OH) 2 D 3 modulates IL-11 signaling by enhancing gp-130 expression in osteoblasts. This modulation may contribute to its action as a bone-resorbing hormone.
g. TNF␣.
TNF␣ is a pleiotropic cytokine with actions on the differentiation, growth, and functional activities of normal and malignant cells from numerous tissues (316) . Its actions on connective tissue cells include the stimulation of bone resorption, cartilage breakdown (317), collagenase production by synovial cells (318) , and the inhibition of rat calvarial bone collagen synthesis (319, 320) . TNF␣ has been shown to reduce VDR expression in the osteoblastic ROS 17/2.8 cell line (321) and thus antagonizes the anabolic effects of the sterol on osteoblasts.
Cells that migrate from fragments of human trabecular bone and form monolayers in culture exhibit characteristics of bone-forming cells or osteoblasts (322, 323) . Recombinant TNF␣ modulates the proliferation and osteoblastic characteristics of these cells in vitro at concentrations between 10 Ϫ12 and 10 Ϫ8 m (324). TNF␣ has been proposed, therefore, as a local mediator of the control of bone turnover in situations of chronic inflammation. It has been shown that human osteoblasts derived as outgrowths from trabecular bone release substantial amounts of TNF␣ in response to IL-1 and granulocyte macrophage colony stimulating factor (GM-CSF), but calcitonin, PTH, and 1␣,25(OH) 2 D 3 have no effect on it (325) . This result suggests that 1␣,25(OH) 2 D 3 does not contribute to TNF-␣-induced bone loss in chronic inflammatory states associated with increased bone resorption.
h. M-CSF and GM-CSF. M-CSF, which is essential for osteoclast development (326, 327) , could be one of the most important signals elaborated by the osteoblast to initiate a cycle of bone remodeling. Regulation of osteoblast M-CSF expression is therefore a significant target site for factors, including 1␣,25(OH) 2 D 3 , that promote osteoclastogenesis. Blocking antibodies against M-CSF prevents osteoclastogenesis by preventing the expansion of the monocytic precursor pool from which osteoclasts arise (327) . M-CSF alone, however, is not sufficient for osteoclastogenesis: in the murine primary culture system the presence of accessory osteoblasts is required, suggesting that osteoblasts may need to present a membrane-bound form of M-CSF to developing monocytic cells (328) . In the osteopetrotic op/op mouse, which expresses a mutant, inactive M-CSF, no osteoclasts or macrophages are found (329, 330) .
The receptor for M-CSF, encoded by the protooncogene c-fms, is found in mature macrophages and osteoclasts as well as the pluripotent precursor (331) . Expression of the M-CSF receptor has been shown to increase in murine bone marrow-derived cells as they mature into monocytes and macrophages, thereby providing a lineage-specific marker of differentiation (332, 333) . 1␣,25(OH) 2 D 3 has been shown to increase M-CSF receptor expression on early uncommitted nonadherent bone marrow precursor cells (334) . Thus, an increase in M-CSF receptor expression may be a mechanism by which 1␣,25(OH) 2 D 3 exerts its differentiational effects on monocyte/macrophage precursors, directly influencing the ability of the cell to bind the cytokine.
Perkins et al. (335) have shed some light on the details of 1␣,25(OH) 2 D 3 -induced M-CSF receptor expression. In bone marrow cells, 1␣,25(OH) 2 D 3 caused a marked decrease in cellular proliferation despite a 2-to 3-fold increase in radiolabeled M-CSF binding in a dose-dependent manner. Scatchard analysis demonstrated that increased binding reflects increased receptor capacity without an alteration in affinity. The steroid accelerated the protein appearance rather than overexpression because treated and untreated cells ultimately exhibited equivalent binding. Increased M-CSF receptor expression was mirrored by increased c-fms mRNA levels, and actinomycin D and cycloheximide experiments indicated that new receptor synthesis, rather than mobilization of intracellular pool, is required (335) . In contrast to these observations, Biskobing et al. (336) have shown that HL-60 cells, which represent an early precursor in myelomonocytic lineage, present with a decreased M-CSF receptor expression in response to 1␣,25(OH) 2 D 3 . Taken together, these findings suggest that the stimulatory effect of 1␣,25(OH) 2 D 3 on M-CSF receptor expression depends on the stage of differentiation of osteoclast precursors.
1␣,25(OH) 2 D 3 is also involved in the regulation of M-CSF synthesis by osteoblastic cells. In an early report by Elford et al. (337) , it was shown that 1␣,25(OH) 2 D 3 is able to induce M-CSF secretion by neonatal mouse calvaria. More recently, Rubin et al. (338) found that M-CSF mRNA expression is increased, in a dose-dependent manner, by 1␣,25(OH) 2 D 3 in murine osteoblastic cells. Furthermore, they also showed that 1␣,25(OH) 2 D 3 is able to stimulate a membrane-bound form of M-CSF in these cells, and this regulation is primarily pretranslational (338) .
Osteoblasts have also been shown to produce GM-CSF, which increases the formation of osteoclast-like cells from bone marrow cells (339) . This activity is enhanced in the presence of 1␣,25(OH) 2 D 3 (339) . In murine MC3T3-E1 cell lines, lipopolysaccharide and, to a lesser extent, PTH are capable of inducing GM-CSF secretion by the cells (340) . However, 1␣,25(OH) 2 D 3 fails to induce GM-CSF production (340) . Therefore, it is unlikely that the interaction between 1␣,25(OH) 2 D 3 and GM-CSF in the context of stimulation of osteoclastogenesis involves a change in the synthesis of cytokine. As discussed below, the stimulation of annexin II by 1␣,25(OH) 2 D 3 results in a GM-CSF-mediated increase in osteoclastogenesis.
i. Annexin II. Annexin II, a calcium-dependent phospholipid-binding protein, has been found recently to be an osteoclast-stimulatory factor that is also secreted by osteoclasts (341) . Annexin II increases osteoclast formation by enhancing proliferation of CFU-GM. This function is accomplished through induction of GM-CSF expression by CD4ϩ T cells (342) . It has been shown that annexin II transcript levels are clearly increased by 1␣,25(OH) 2 D 3 treatment of human bone marrow osteoclast-like cells (342) . These results suggest that annexin II is an important mediator of the effects of 1␣,25(OH) 2 D 3 on osteoclastogenesis and involves GM-CSF.
V. Summary and Future Directions
In the past several years, numerous studies have suggested that 1␣,25(OH) 2 D 3 interacts with various growth factors and cytokines to mediate its effects in coordinating cell growth and differentiation. This interaction may occur in a variety of cell types including epithelial, mesenchymal, neural, and endothelial cells. In this review, however, we have confined our remarks to its effects in keratinocyte and bone cell (osteoblasts and osteoclasts) biology, both of which are regulated by tightly coordinated local control mechanisms and are highly illustrative of relevant 1␣,25(OH) 2 D 3 -growth factor/cytokine interactions.
The effect of 1␣,25(OH) 2 D 3 on keratinocyte growth is controversial with proliferative and antiproliferative effects being observed in different studies. This discrepancy has been attributed to the range of 1␣,25(OH) 2 D 3 concentrations and medium conditions used in in vitro cultures. The antiproliferative effect is predominant in proliferative states such as psoriasis and is due to excessive expression of VDR. The stimulatory effect is mediated by increases in EGF-related growth factors and its receptors, and this is valid in normal skin in which the cells are not proliferative. In contrast, the inhibitory effects are mediated by increases in TGF␤. The induction of TNF␣ and increased ceramide formation may account for, at least in part, the prodifferentiative effects of the sterol on keratinocytes. Proinflammatory cytokines IL-1␣, IL-6, IL-8, and RANTES are all suppressed by 1␣,25(OH) 2 D 3 , possibly explaining why the sterol is topically effective in the treatment of hyperproliferative skin disorders such as psoriasis. PDGF, a growth factor implicated in wound healing, is induced in epidermal keratinocytes by 1␣,25(OH) 2 D 3 . This may provide a further rationale for the beneficial effects of the sterol in corticosteroid or age-induced cutaneous atrophy and sun-related skin damage, and substantiates the contribution of keratinocytes in the wound healing process. 1␣,25(OH) 2 D 3 plays a crucial role in bone resorption by stimulating osteoclast formation and activity. Unlike osteoblasts, however, osteoclasts do not express the VDR. Therefore, they are indirectly regulated by 1␣,25(OH) 2 D 3 . Many cytokines and growth factors involved in the regulation of osteoclastogenesis and osteoclast function are modulated by 1␣,25(OH) 2 D 3 . The recently discovered RANKL/RANK/ OPG cytokine system has paramount importance in the local control of osteoclast biology. By activating the RANKL and suppressing its decoy receptor, OPG, 1␣,25(OH) 2 D 3 enhances osteoclastogenesis and bone resorption. Several other cytokines and growth factors, which stimulate (IL-1, IL-6, IL-11, annexin II) or inhibit (IL-4, M-CSF, TGF␤) bone resorption, are regulated by 1␣,25(OH) 2 D 3 . TNF␣, a cytokine involved in local bone loss associated with inflammatory disorders, does not seem to be influenced by 1␣,25(OH) 2 D 3 , although further investigation is required in this area.
In conclusion, strong and mounting evidence suggests that 1␣,25(OH) 2 D 3 -mediated effects on cytokine/growth factor synthesis and signaling are important in the local regulation of cellular growth and differentiation. A valid shortcoming in experimental information, however, is that most of the data are derived from in vitro studies. Clearly, in vitro results are not always representative of the effects in vivo. Therefore, further in vivo studies are needed to delineate and validate these interactions, preferably using cytokine/growth factor overexpressing or receptor knockout animals. Also, there remain unknown or ill-defined molecular mechanisms mediating the effects of 1␣,25(OH) 2 D 3 . Future research should focus, in particular, on the postreceptor mechanisms (e.g., Smads and Smad partners) implicated in these effects. Also, further investigations are needed to fully elucidate the function of 1␣,25(OH) 2 D 3 in the regulation of other cytokines and growth factors involved in bone cell biology, such as PDGF, leukemia inhibitory factor, IFN␥, and other novel mediators. Reversible inhibition of normal human prokeratinocyte proliferation by type ␤ transforming growth factor-growth inhibitor in serum-free medium. 
